Williams David S
Departments of Pharmacology and Neurosciences, UCSD School of Medicine, Mail Code 0912, 9500 Gilman Drive, La Jolla, CA 92093-0912, USA.
Vision Res. 2008 Feb;48(3):433-41. doi: 10.1016/j.visres.2007.08.015. Epub 2007 Oct 23.
Usher syndrome is a deafness-blindness disorder. The blindness occurs from a progressive retinal degeneration that begins after deafness and after the retina has developed. Three clinical subtypes of Usher syndrome have been identified, with mutations in any one of six different genes giving rise to type 1, in any one of three different genes to type 2, and in one identified gene causing Usher type 3. Mutant mice for most of the genes have been studied; while they have clear inner ear defects, retinal phenotypes are relatively mild and have been difficult to characterize. The retinal functions of the Usher proteins are still largely unknown. Protein binding studies have suggested many interactions among the proteins, and a model of interaction among all the proteins in the photoreceptor synapse has been proposed. However this model is not supported by localization data from some laboratories, or the indication of any synaptic phenotype in mutant mice. An earlier suggestion, based on patient pathologies, of Usher protein function in the photoreceptor cilium continues to gain support from immunolocalization and mutant mouse studies, which are consistent with Usher protein interaction in the photoreceptor ciliary/periciliary region. So far, the most characterized Usher protein is myosin VIIa. It is present in the apical RPE and photoreceptor ciliary/periciliary region, where it is required for organelle transport and clearance of opsin from the connecting cilium, respectively. Usher syndrome is amenable to gene replacement therapy, but also has some specific challenges. Progress in this treatment approach has been achieved by correction of mutant phenotypes in Myo7a-null mouse retinas, following lentiviral delivery of MYO7A.
尤塞氏综合征是一种致聋致盲的疾病。失明是由进行性视网膜变性引起的,这种变性在耳聋之后且视网膜发育完成后开始。尤塞氏综合征已被鉴定出三种临床亚型,六个不同基因中的任何一个发生突变会导致1型,三个不同基因中的任何一个发生突变会导致2型,而一个已确定的基因发生突变会导致3型尤塞氏综合征。大多数这些基因的突变小鼠已被研究;虽然它们有明显的内耳缺陷,但视网膜表型相对较轻且难以特征化。尤塞氏蛋白的视网膜功能在很大程度上仍然未知。蛋白质结合研究表明这些蛋白质之间有许多相互作用,并且已经提出了光感受器突触中所有蛋白质之间的相互作用模型。然而,这个模型并不得到一些实验室的定位数据的支持,也没有在突变小鼠中发现任何突触表型的迹象。基于患者病理情况的一个早期观点,即尤塞氏蛋白在光感受器纤毛中的功能,继续从免疫定位和突变小鼠研究中获得支持,这些研究与尤塞氏蛋白在光感受器纤毛/纤毛周围区域的相互作用是一致的。到目前为止,研究得最清楚的尤塞氏蛋白是肌球蛋白VIIa。它存在于顶端视网膜色素上皮和光感受器纤毛/纤毛周围区域,分别在细胞器运输和视蛋白从连接纤毛清除过程中发挥作用。尤塞氏综合征适合进行基因替代疗法,但也有一些特殊挑战。通过慢病毒递送MYO7A后纠正Myo7a基因敲除小鼠视网膜中的突变表型,在这种治疗方法上已经取得了进展。